PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/srep42319
Abstract: Emerging evidence has shown that adding poly(ADP-ribose) polymerase (PARP) inhibitors to chemotherapy regimens is superior to the control regimens alone in BRCA1-mutated triple-negative breast cancer (TNBC) patients, but their underlying mechanisms have not been fully… read more here.
Keywords: mir 664b; chemosensitivity; mutated triple; brca1 mutated ... See more keywords
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer
Sign Up to like & getrecommendations! Published in 2017 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.aal4922
Abstract: BRCA1-mutated tumors may be particularly vulnerable to dual checkpoint inhibition. Bringing out the neoantigens Immune checkpoint inhibitors are becoming increasingly popular and successful for the treatment of cancer, but they have not gained much ground… read more here.
Keywords: immune checkpoint; breast; brca1; brca1 mutated ... See more keywords
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-16-2796
Abstract: Purpose: Rucaparib is a potent, oral, small-molecule PARP inhibitor. This phase I–II study was the first to evaluate single-agent oral rucaparib at multiple doses. Experimental Design: Part 1 (phase I) sought to determine the MTD,… read more here.
Keywords: brca1 mutated; rucaparib; parp inhibitor; phase study ... See more keywords
Abstract 1125: Eukaryotic Elongation Factor 2 Kinase (eEF-2K) is a novel therapeutic target in BRCA1+ mutated breast cancer
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-1125
Abstract: BReast CAncer 1 and 2 (BRCA1/2) tumor suppressor genes are frequently mutated in familial breast and ovarian cancers. Recent clinical trials in breast cancers with BRCA1/2 mutations indicate that 50-75% of patients may not have… read more here.
Keywords: kinase; brca1; brca1 mutated; breast cancer ... See more keywords
Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.6070
Abstract: 6070Background: Olaparib maintenance is a standard treatment of BRCA1/2 mutated platinum-sensitive recurrent EOC. Despite improvement in PFS, olaparib (O) resistance often occurs and the optimal ma... read more here.
Keywords: platinum sensitive; mutated platinum; sensitive recurrent; brca1 mutated ... See more keywords
EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Nanomedicine"
DOI: 10.2217/nnm-2019-0132
Abstract: Aim: To investigate the role of EF2K in BRCA1-mutated breast cancer. Materials & methods: We developed silica coated cobalt-ferrite (CoFe) nanoparticles for in vivo delivery of small interfering RNAs (siRNAs) into BRCA1-mutated breast cancer. Results: Expression of EF2K… read more here.
Keywords: mutated breast; cobalt ferrite; breast cancer; brca1 mutated ... See more keywords